FFAI
Faraday Future cut notes payable, derivative and payable liabilities to lift stockholders' equity by about $20 million and says it met Nasdaq's equity standard as of July 31.
ADPT
Updated NCCN myeloma guidelines add a dedicated MRD testing page and name clonoSEQ as the only assay specifically cited, with 10-6 sensitivity preferred.
AQST
Aquestive Therapeutics has refiled its New Drug Application for Anaphylm sublingual epinephrine film after completing the human factors and PK studies the FDA demanded.
AQST
Aquestive has refiled its application for the needle-free epinephrine film Anaphylm, backed by new human factors and pharmacokinetic data.
WOLF
Pro forma filing shows $1.3 billion of new secured notes, roughly 43.6 million new shares and a $10 million escrow gain after regulatory clearances landed.
IBG
The Australian drinks group says its audited 2024 financial statements can no longer be relied upon, with net loss restated to $4.7 million from $2.57 million.
XCUR
Exicure has until December 2, 2026 to show at least $2.5 million in stockholders' equity or face a delisting determination it could appeal.
Regulatory
Isku Inspira, holding 10.37% of Martela's shares, wants an EGM on a special audit of the Finnish furniture maker's accounts and its planned directed share issue.
NRXP
The FDA reclassified an amendment to NRx's generic application for preservative-free IV ketamine as minor, setting a GDUFA goal date of November 10, 2026.
Regulatory
Iceland's Ásar hf. says the competition regulator's preliminary view is that remedies are needed for its purchases of Öryggismiðstöð Íslands and Opin kerfi.
WNW
Meiwu holders backed a share reclassification that converts 135,073 shares into Class B stock carrying 150 votes each, concentrating voting power with chairman Changbin Xia.
NRXP
NRx says the FDA downgraded an ANDA amendment for preservative-free ketamine from major to minor and set a new GDUFA goal date of November 10, 2026.